Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DHR US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DHR US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Danaher Corp /DE/(DHR US)

$233.02+0.860.37%Ext:$234.95+1.930.83%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Danaher Corp /DE/(DHR US)

$233.02+0.860.37%Ext:$234.95+1.930.83%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Danaher Corp /DE/ — Company Profile

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Sector
Information Technology
Industry
Electronic Equipment, Instruments & Components
Exchange
UN
CEO
Rainer Blair
Headquarters
Washington, DC, US

Danaher Corp /DE/ — Company Profile

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Sector
Information Technology
Industry
Electronic Equipment, Instruments & Components
Exchange
UN
CEO
Rainer Blair
Headquarters
Washington, DC, US
IPO Date
Dec 29, 1978
Employees
59,000
Website
www.danaher.com

Key Metrics

Price
$214.06
Market Cap
$150.48B
Revenue (TTM)
$5.95B
Net Income (TTM)
$1.03B
EPS (TTM)
1.45
P/E (TTM)
40.79
P/B (TTM)
2.84
Dividend Yield
78.83%
ROE (TTM)
1.94%
ROA (TTM)
1.23%
Operating Margin
22.58%
Beta
0.62

Dividends

Last Dividend
$0.40
Last Yield
0.79%

Summary

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Website
www.danaher.com
Location
Washington, DC, US
Phone202 828 0850
Employees59,000
CEORainer Blair
Sector
Information Technology
Industry
Electronic Equipment, Instruments & Components
IPO DateDec 29, 1978

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.7K)

Expand
  • Form 4McGrew Matthew10 Nov
  • Form 4Milosevich Gregory M10 Nov
  • Form 144Couchara Georgeann10 Nov
  • Form 144McGrew Matthew9 Nov
  • Form 144Blair Rainer9 Nov
  • Form 144Milosevich Gregory M9 Nov
  • SC 13GDANAHER CORP /DE/5 Nov
  • Form 4Zerhouni Elias A.2 Nov
  • Form 4Dewan Feroz2 Nov
  • Form 4FILLER LINDA2 Nov
  • Form 4List Teri2 Nov
  • Form 4Stevens Raymond C2 Nov
  • Form 4Sanders A Shane2 Nov
  • Form 4SPOON ALAN G2 Nov
  • Form 4Bouda Christopher29 Oct
  • Form 4McGrew Matthew29 Oct
  • Form 144McGrew Matthew28 Oct
  • 8-KResults of Operations and Financial Condition20 Oct
  • 10-QQ3ended 25 Sept 202620 Oct
  • Form 3COMAS DANIEL L16 Oct

News

  • CenterBook Partners LP Purchases 2,610 Shares of Danaher Corporation $DHR12 Nov
  • VTRS or DHR: Which Is the Better Value Stock Right Now?10 Nov
  • Allspring Global Investments Holdings LLC Sells 52,246 Shares of Danaher Corporation $DHR10 Nov
  • Danaher Corporation $DHR Position Raised by Commonwealth Equity Services LLC10 Nov
  • Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus9 Nov
  • Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript9 Nov
  • Danaher Corporation $DHR Shares Newly Purchased by Associated Banc Corp4 Nov
  • International Assets Investment Management LLC Purchases 7,846 Shares of Danaher Corporation $DHR3 Nov
  • Danaher Corporation $DHR Holdings Trimmed by Bank Julius Baer & Co. Ltd Zurich3 Nov
  • Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences2 Nov
  • Danaher (DHR) Upgraded to Buy: Here's Why27 Oct
  • Danaher Corporation $DHR Shares Sold by Compass Wealth Management LLC23 Oct
  • Danaher Corporation $DHR Shares Newly Acquired by Cantor Fitzgerald Investment Advisors L.P.23 Oct
  • LH vs. DHR: Which Stock Is the Better Value Option?22 Oct
  • Danaher Q3 Recap: Decent Results, Still A Hold22 Oct
  • Why Danaher Stock Bounced Higher Today21 Oct
  • Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript21 Oct
  • Danaher: 3 Key Takeaways for Long-Term Investors21 Oct
  • Danaher Corp (DHR) (Q3 2026) Earnings Call Highlights: Core Growth Accelerates to 5.5% Ex-Respiratory as EPS Guidance Rises21 Oct
  • Danaher Q3 Review: Interested To See What The New Management Will Bring21 Oct

Mentions in Filings

  • … re Partners, a venture capital fund backed by BBVA Group, from 2017 to 2021. Mr. van de Vyver also served as a consultant from 2015 to 2017 for CrossCountry Consulting, where his clients included Lending Club (NYSE: LC), <strong>Danaher</strong> (NYSE: DHR) and Marriott Vacations Worldwide Corp (NYSE: VAC). Mr. van de Vyver obtained his bachelor’s in accounting from Stellenbosch University, South Africa in 2010 and his Honors degree in Accounting in 2011 from Ste …
    Launch Two Acquisition Corp.Danaher Corp /DE/·S-4/A - REGISTRATION STATEMENT·Q4 26·12 Nov
  • … ific, Middle East, Hong Kong/Shanghai and China, from 2012 until 2015. Joakim Weidemanis, 57, has served as Chief Executive Officer since March 2025. Mr. Weidemanis previously served as Executive Vice President of <strong>Danaher Corporation</strong>, a leading global life sciences and diagnostics innovator, from 2017 until 2024. Prior to becoming Executive Vice President, Mr. Weidemanis held various management positions within Danaher from 2011 until 2017. Prio …
    Johnson Controls International plcDanaher Corp /DE/·10-K - Annual report FY 2026·FY26·12 Nov
  • … sciences technology and the diagnostic companies that are supplying components, products and services that serve customers engaged in proteomics analysis. These companies include Agilent Technologies, Bio-Techne, Bruker, <strong>Danaher</strong>, DiaSorin, Illumina and Thermo Fisher Scientific. We also compete with a number of companies that have developed, or are developing, proteomic products and solutions, such as Alamar Biosciences, Nautilus Biotechnology, Qu …
    Seer, Inc.Danaher Corp /DE/·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … 7. Mr. Murphy was appointed Co-Chief Operating Officer in August 2025. He previously served as Executive Vice President from October 2019 to August 2025 and as President of HarcoSemco from December 2014 to September 2019. Prior to joining TransDigm, Mr. Murphy was Vice President and General Manager for two <strong>Danaher Corporation</strong> businesses and held several other senior leadership roles in the industrial manufacturing and high-technology industries.
    TransDigm Group INCDanaher Corp /DE/·10-K - Annual report FY 2026·FY26·10 Nov
  • … s, covers a wide range of dentists’ clinical needs for diagnosing, treating and preventing dental conditions as well as improving the human smile. We further support the dental community with leading solutions in restoratives, endodontics, rotary, infection prevention and loupes. We were formed in 2018 as a wholly-owned subsidiary of <strong>Danaher Corporation</strong> and, in 2019, we completed our initial public offering and separated from Danaher Corporation.
    Envista Holdings CorpDanaher Corp /DE/·S-3ASR - REGISTRATION STATEMENT·Q4 26·9 Nov
  • … umber of applications for cell analysis, and more particularly flow cytometry, is leading to more companies offering competitive products and services. Our competitors include Agilent Technologies, Beckman Coulter (<strong>Danaher Corporation</strong>), Bio-Rad Laboratories, Standard BioTools Inc., Miltenyi Biotec, Sony Biotechnology (Sony Corporation), Thermo Fisher Scientific, and Waters Corporation. Our target customers may also elect to develop their workflow …
    Cytek Biosciences, Inc.Danaher Corp /DE/·10-Q - Quarterly report Q3·Q3 26·4 Nov

Key Stats

Trading

Px/Chg 1D$214.06 / +1.09%
Avg Volume4.39M
Beta0.62
Mkt Cap150.48B
FD Mkt Cap150.14B

Float

Shrs Out/Float702.99M / 625.84M
Short Float0.02%
Days to Cover2.39
Stock Repurchased$9.00M

Current Valuation

EV163.27B
EV/EBITDA24.57
EV/Sales6.59
P/B2.84
P/S6.07
FCF Yield0.72%
ROE1.94%
ROA1.23%
Current Ratio1.87

Dividend

Cash$0.40
Yield78.83%
Yield (TTM)78.83%

Estimates

P/E40.79
Est P/E0.00
Est EPS1.94
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings71.4322.6836.5034.68115.52147.78
Price / Sales12.976.147.285.6620.2225.55
Price / Book Value2.953.263.252.732.632.87
Price / Free Cash Flow59.4322.1930.0825.5379.20140.15
ENTERPRISE VALUE METRICS
Enterprise Value166,910.5179,778.0187,548.9150,280.8152,087.2164,857.4
Enterprise Value / Sales14.176.757.856.2922.2427.70
Enterprise Value / EBITDA49.8718.9525.0120.6574.15110.57
Enterprise Value / EBIT64.7324.4535.1730.52106.50127.01

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-4.4%29,453.026,643.023,890.023,875.024,568.0
Gross Income-4.4%17,952.016,188.014,034.014,206.014,970.0
EBITDA-8.7%10,007.09,485.07,499.07,276.06,945.0
EBIT-13%7,839.07,353.05,333.04,924.04,498.0
Net Income-13.4%6,433.07,209.04,764.03,899.03,614.0
EPS (Diluted)-12.5%8.619.646.385.295.04
BALANCE SHEET
Cash & ST Inv15.6%2,586.05,995.05,864.02,078.04,615.0
Total Assets8.4%83,184.084,350.084,488.077,542.083,464.0
Total Liabilities-5%38,007.034,260.030,998.027,992.030,930.0
Total Shareholder Equity3.8%45,167.050,082.053,486.049,543.052,534.0
CASH FLOW
Net Operating Cash Flow-6.4%8,358.08,519.07,164.06,688.06,416.0
Cap Ex-2.8%-1,294.0-1,152.0-1,383.0-1,392.0-1,156.0
Free Cash Flow-7.1%7,064.07,367.05,781.05,296.05,260.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)230.58
Basic Shares702.99
Market Cap162,091.0
Diluted Shares706.80
Fully Diluted Shares Outstanding706.80
Fully Diluted Market Cap162,970.4
+Consolidated Debt26,482.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-5,682.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest12.0
+Pension Liabilities—
Enterprise Value182,903.0

Segment data

Revenue

by Products and services

  • Revenue From Contract With Customer, Measurement, Recurring82%
  • Revenue From Contract With Customer, Measurement, Nonrecurring18%

Revenue

by Geography

  • Other Developed Markets82%
  • China18%

Related companies

Teradyne, Inc

TER US

Keysight Technologies Inc.

KEYS US

Ametek Inc/

AME US

Compagnie De Saint Gobain

CODYY US

Roper Technologies Inc

ROP US

China Jushi Co., Ltd.

600176 CG

Veralto Corp

VLTO US

Kingspan Group plc

KGSPY US

Mks Inc

MKSI US

Fortive Corp

FTV US

Toromont Industries Ltd./ADR

TMTNF US

QXO, Inc.

QXO US

IPO Date
Dec 29, 1978
Employees
59,000
Website
www.danaher.com

Key Metrics

Price
$214.06
Market Cap
$150.48B
Revenue (TTM)
$5.95B
Net Income (TTM)
$1.03B
EPS (TTM)
1.45
P/E (TTM)
40.79
P/B (TTM)
2.84
Dividend Yield
78.83%
ROE (TTM)
1.94%
ROA (TTM)
1.23%
Operating Margin
22.58%
Beta
0.62

Dividends

Last Dividend
$0.40
Last Yield
0.79%

Summary

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Website
www.danaher.com
Location
Washington, DC, US
Phone202 828 0850
Employees59,000
CEORainer Blair
Sector
Information Technology
Industry
Electronic Equipment, Instruments & Components
IPO DateDec 29, 1978

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.7K)

Expand
  • Form 4McGrew Matthew10 Nov
  • Form 4Milosevich Gregory M10 Nov
  • Form 144Couchara Georgeann10 Nov
  • Form 144McGrew Matthew9 Nov
  • Form 144Blair Rainer9 Nov
  • Form 144Milosevich Gregory M9 Nov
  • SC 13GDANAHER CORP /DE/5 Nov
  • Form 4Zerhouni Elias A.2 Nov
  • Form 4Dewan Feroz2 Nov
  • Form 4FILLER LINDA2 Nov
  • Form 4List Teri2 Nov
  • Form 4Stevens Raymond C2 Nov
  • Form 4Sanders A Shane2 Nov
  • Form 4SPOON ALAN G2 Nov
  • Form 4Bouda Christopher29 Oct
  • Form 4McGrew Matthew29 Oct
  • Form 144McGrew Matthew28 Oct
  • 8-KResults of Operations and Financial Condition20 Oct
  • 10-QQ3ended 25 Sept 202620 Oct
  • Form 3COMAS DANIEL L16 Oct

News

  • CenterBook Partners LP Purchases 2,610 Shares of Danaher Corporation $DHR12 Nov
  • VTRS or DHR: Which Is the Better Value Stock Right Now?10 Nov
  • Allspring Global Investments Holdings LLC Sells 52,246 Shares of Danaher Corporation $DHR10 Nov
  • Danaher Corporation $DHR Position Raised by Commonwealth Equity Services LLC10 Nov
  • Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus9 Nov
  • Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript9 Nov
  • Danaher Corporation $DHR Shares Newly Purchased by Associated Banc Corp4 Nov
  • International Assets Investment Management LLC Purchases 7,846 Shares of Danaher Corporation $DHR3 Nov
  • Danaher Corporation $DHR Holdings Trimmed by Bank Julius Baer & Co. Ltd Zurich3 Nov
  • Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences2 Nov
  • Danaher (DHR) Upgraded to Buy: Here's Why27 Oct
  • Danaher Corporation $DHR Shares Sold by Compass Wealth Management LLC23 Oct
  • Danaher Corporation $DHR Shares Newly Acquired by Cantor Fitzgerald Investment Advisors L.P.23 Oct
  • LH vs. DHR: Which Stock Is the Better Value Option?22 Oct
  • Danaher Q3 Recap: Decent Results, Still A Hold22 Oct
  • Why Danaher Stock Bounced Higher Today21 Oct
  • Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript21 Oct
  • Danaher: 3 Key Takeaways for Long-Term Investors21 Oct
  • Danaher Corp (DHR) (Q3 2026) Earnings Call Highlights: Core Growth Accelerates to 5.5% Ex-Respiratory as EPS Guidance Rises21 Oct
  • Danaher Q3 Review: Interested To See What The New Management Will Bring21 Oct

Mentions in Filings

  • … re Partners, a venture capital fund backed by BBVA Group, from 2017 to 2021. Mr. van de Vyver also served as a consultant from 2015 to 2017 for CrossCountry Consulting, where his clients included Lending Club (NYSE: LC), <strong>Danaher</strong> (NYSE: DHR) and Marriott Vacations Worldwide Corp (NYSE: VAC). Mr. van de Vyver obtained his bachelor’s in accounting from Stellenbosch University, South Africa in 2010 and his Honors degree in Accounting in 2011 from Ste …
    Launch Two Acquisition Corp.Danaher Corp /DE/·S-4/A - REGISTRATION STATEMENT·Q4 26·12 Nov
  • … ific, Middle East, Hong Kong/Shanghai and China, from 2012 until 2015. Joakim Weidemanis, 57, has served as Chief Executive Officer since March 2025. Mr. Weidemanis previously served as Executive Vice President of <strong>Danaher Corporation</strong>, a leading global life sciences and diagnostics innovator, from 2017 until 2024. Prior to becoming Executive Vice President, Mr. Weidemanis held various management positions within Danaher from 2011 until 2017. Prio …
    Johnson Controls International plcDanaher Corp /DE/·10-K - Annual report FY 2026·FY26·12 Nov
  • … sciences technology and the diagnostic companies that are supplying components, products and services that serve customers engaged in proteomics analysis. These companies include Agilent Technologies, Bio-Techne, Bruker, <strong>Danaher</strong>, DiaSorin, Illumina and Thermo Fisher Scientific. We also compete with a number of companies that have developed, or are developing, proteomic products and solutions, such as Alamar Biosciences, Nautilus Biotechnology, Qu …
    Seer, Inc.Danaher Corp /DE/·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … 7. Mr. Murphy was appointed Co-Chief Operating Officer in August 2025. He previously served as Executive Vice President from October 2019 to August 2025 and as President of HarcoSemco from December 2014 to September 2019. Prior to joining TransDigm, Mr. Murphy was Vice President and General Manager for two <strong>Danaher Corporation</strong> businesses and held several other senior leadership roles in the industrial manufacturing and high-technology industries.
    TransDigm Group INCDanaher Corp /DE/·10-K - Annual report FY 2026·FY26·10 Nov
  • … s, covers a wide range of dentists’ clinical needs for diagnosing, treating and preventing dental conditions as well as improving the human smile. We further support the dental community with leading solutions in restoratives, endodontics, rotary, infection prevention and loupes. We were formed in 2018 as a wholly-owned subsidiary of <strong>Danaher Corporation</strong> and, in 2019, we completed our initial public offering and separated from Danaher Corporation.
    Envista Holdings CorpDanaher Corp /DE/·S-3ASR - REGISTRATION STATEMENT·Q4 26·9 Nov
  • … umber of applications for cell analysis, and more particularly flow cytometry, is leading to more companies offering competitive products and services. Our competitors include Agilent Technologies, Beckman Coulter (<strong>Danaher Corporation</strong>), Bio-Rad Laboratories, Standard BioTools Inc., Miltenyi Biotec, Sony Biotechnology (Sony Corporation), Thermo Fisher Scientific, and Waters Corporation. Our target customers may also elect to develop their workflow …
    Cytek Biosciences, Inc.Danaher Corp /DE/·10-Q - Quarterly report Q3·Q3 26·4 Nov

Key Stats

Trading

Px/Chg 1D$214.06 / +1.09%
Avg Volume4.39M
Beta0.62
Mkt Cap150.48B
FD Mkt Cap150.14B

Float

Shrs Out/Float702.99M / 625.84M
Short Float0.02%
Days to Cover2.39
Stock Repurchased$9.00M

Current Valuation

EV163.27B
EV/EBITDA24.57
EV/Sales6.59
P/B2.84
P/S6.07
FCF Yield0.72%
ROE1.94%
ROA1.23%
Current Ratio1.87

Dividend

Cash$0.40
Yield78.83%
Yield (TTM)78.83%

Estimates

P/E40.79
Est P/E0.00
Est EPS1.94
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings71.4322.6836.5034.68115.52147.78
Price / Sales12.976.147.285.6620.2225.55
Price / Book Value2.953.263.252.732.632.87
Price / Free Cash Flow59.4322.1930.0825.5379.20140.15
ENTERPRISE VALUE METRICS
Enterprise Value166,910.5179,778.0187,548.9150,280.8152,087.2164,857.4
Enterprise Value / Sales14.176.757.856.2922.2427.70
Enterprise Value / EBITDA49.8718.9525.0120.6574.15110.57
Enterprise Value / EBIT64.7324.4535.1730.52106.50127.01

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-4.4%29,453.026,643.023,890.023,875.024,568.0
Gross Income-4.4%17,952.016,188.014,034.014,206.014,970.0
EBITDA-8.7%10,007.09,485.07,499.07,276.06,945.0
EBIT-13%7,839.07,353.05,333.04,924.04,498.0
Net Income-13.4%6,433.07,209.04,764.03,899.03,614.0
EPS (Diluted)-12.5%8.619.646.385.295.04
BALANCE SHEET
Cash & ST Inv15.6%2,586.05,995.05,864.02,078.04,615.0
Total Assets8.4%83,184.084,350.084,488.077,542.083,464.0
Total Liabilities-5%38,007.034,260.030,998.027,992.030,930.0
Total Shareholder Equity3.8%45,167.050,082.053,486.049,543.052,534.0
CASH FLOW
Net Operating Cash Flow-6.4%8,358.08,519.07,164.06,688.06,416.0
Cap Ex-2.8%-1,294.0-1,152.0-1,383.0-1,392.0-1,156.0
Free Cash Flow-7.1%7,064.07,367.05,781.05,296.05,260.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)230.58
Basic Shares702.99
Market Cap162,091.0
Diluted Shares706.80
Fully Diluted Shares Outstanding706.80
Fully Diluted Market Cap162,970.4
+Consolidated Debt26,482.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-5,682.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest12.0
+Pension Liabilities—
Enterprise Value182,903.0

Segment data

Revenue

by Products and services

  • Revenue From Contract With Customer, Measurement, Recurring82%
  • Revenue From Contract With Customer, Measurement, Nonrecurring18%

Revenue

by Geography

  • Other Developed Markets82%
  • China18%

Related companies

Teradyne, Inc

TER US

Keysight Technologies Inc.

KEYS US

Ametek Inc/

AME US

Compagnie De Saint Gobain

CODYY US

Roper Technologies Inc

ROP US

China Jushi Co., Ltd.

600176 CG

Veralto Corp

VLTO US

Kingspan Group plc

KGSPY US

Mks Inc

MKSI US

Fortive Corp

FTV US

Toromont Industries Ltd./ADR

TMTNF US

QXO, Inc.

QXO US